Nano-X Imaging Ltd.
Nano-X Imaging, or Nanox, provides an integrated medical imaging and healthcare services platform for healthcare providers. Its products and services include Nanox.ARC and Nanox.ARC X digital tomosynthesis imaging systems, Nanox.CLOUD software, Nanox AI imaging analysis, remote radiology and cardiology services through USARAD and Nanox.MARKETPLACE, and healthcare IT services through Nanox Health IT. Nanox AI offers software to hospitals, health maintenance organizations, integrated delivery networks, insurers and other organizations to analyze existing CT scans. Nanox Health IT serves hospitals and other healthcare organizations with implementation, infrastructure and managed IT services. Nanox also provides Nanox.CONNECT, which links 2D X-ray systems to its cloud and marketplace for remote readings. It earns money through imaging system sales and usage-based subscriptions, service contracts and cloud connectivity, AI software offerings, teleradiology interpretations, and healthcare IT services. Its principal executive offices are in Petach Tikva, Israel.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Nano-X Imaging (NNOX) signed a distribution deal with Dosy Health for its cardiac AI solution in Thailand. No purchase commitments or regulatory approvals are in place yet, and commercialization is pending further agreements. According to the company, hospital discussions are preliminary.
Nanox Imaging Ltd. (NNOX) aims to cut annualized GAAP and non-GAAP operating expenses by 25%–30%, excluding one-time restructuring costs, by Q1 2027. The plan includes $2M in annual savings from South Korea restructuring. The company faces liquidity pressure and needs to provide updates on expense reductions and financing.
Nanox Imaging Ltd. (NASDAQ: NNOX) presented clinical data on its AI solution for detecting aortic valve calcification (AVC) at the TCT Conference. The HealthAVC solution demonstrated 98.3% sensitivity and 96.6% specificity in identifying AVC from routine CT scans, highlighting a significant gap in radiology reports. The study, published in JACC: Advances, analyzed 440 scans and found that 84.3% of AVC-positive cases were unreported.
Over the past 7 days, AlphAI's AI scored 4 news stories mentioning NNOX (Nano-X Imaging Ltd.). Coverage has been balanced: 1 bullish, 2 neutral, and 1 bearish.
Recent NNOX coverage spans financial news, technology and earnings.
In the last 30 days, NNOX insiders filed 1 SEC Form 4 transaction — 1 purchase ($11K) and no sales. The most active reporter was Meltzer Erez, Chief Executive Officer, with 1 filing.
The agreement is early-stage with no purchase commitments, so any price impact is likely modest and speculative.
Cost‑reduction guidance may improve cash‑burn outlook and support the stock.
Potential boost to Nanox's AI health platform adoption and future revenue.
The activist stake and opposition to dilutive share increase may pressure the stock lower.
Guidance downgrade and liquidity warning likely pressure the stock.
AlphAI scores every news story that mentions NNOX with an AI model for sentiment and relevance, and aggregates insider trades from Nano-X Imaging Ltd.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Nano-X Imaging (NNOX) signed a distribution deal with Dosy Health for its cardiac AI solution in Thailand. No purchase commitments or regulatory approvals are in place yet, and commercialization is pending further agreements. According to the company, hospital discussions are preliminary.
Nanox Imaging Ltd. (NNOX) aims to cut annualized GAAP and non-GAAP operating expenses by 25%–30%, excluding one-time restructuring costs, by Q1 2027. The plan includes $2M in annual savings from South Korea restructuring. The company faces liquidity pressure and needs to provide updates on expense reductions and financing.
Nanox Imaging Ltd. (NASDAQ: NNOX) presented clinical data on its AI solution for detecting aortic valve calcification (AVC) at the TCT Conference. The HealthAVC solution demonstrated 98.3% sensitivity and 96.6% specificity in identifying AVC from routine CT scans, highlighting a significant gap in radiology reports. The study, published in JACC: Advances, analyzed 440 scans and found that 84.3% of AVC-positive cases were unreported.
Moshe Moalem disclosed an 8.49% stake in Nano-X Imaging (NNOX), opposing a proposed share authorization increase. He plans to discuss the company's strategy and may seek board changes or legal action. Moalem owns 6.67 million shares directly and through Tanir Corporation.
Nano-X Imaging Ltd. (NNOX) reported preliminary Q3 revenue of $4.3–$4.4M, up from $3.4M YoY, and $26.0M in cash. Management indicated liquidity concerns, raising going-concern doubts. The company needs to secure funding or accelerate deployments to mitigate risks.
Nano-X Imaging's subsidiary, Nanox AI, signed a distribution deal with Technologic s.r.l. to sell HealthOST in Italy. This marks an early commercialization step for Nanox AI. Nano-X Imaging announced the agreement.
Nanox Imaging Ltd. (NASDAQ: NNOX) announced that its Nanox.ARC X system was selected as one of TIME’s Best Inventions of 2026. The system offers 3D imaging with up to 80% less radiation than CT scans. This is Nanox’s second appearance on TIME’s list, marking its first inclusion on the main list. The company plans to showcase the system at the RSNA 2026 Annual Meeting.
Nano-X Imaging (NNOX) received a Nasdaq notice that its shares no longer meet the minimum bid-price requirement of $1.00. The company has until March 29, 2027, to regain compliance, with a potential 180-day extension if it transfers to Nasdaq Capital Market. NNOX is considering options to meet the requirement.
Nanox.AI, a subsidiary of Nano-X Imaging Ltd. (NNOX), signed a 3-year UK reseller agreement with Vertec Scientific for its HealthOST bone solution. Separately, it partnered with Intel to optimize its AI framework for local hospital hardware. The company aims to leverage additional anatomical data from CT scans to support clinical evaluations. According to Nanox, 86,000 vertebral fragility fractures occur annually in the UK, many undiagnosed.
Nanox reports Q2 revenue of $4.2 million, highlighting its integrated imaging ecosystem. The company aims to expand access to 3D imaging and diagnostics with its Nanox.ARC system, which is FDA-cleared. Nanox addresses global disparities in imaging technology access, with a focus on lower adoption barriers.
